PPA
CTKB icon

Parametric Portfolio Associates’s Cytek Biosciences CTKB Stock Holding History

Parametric Portfolio Associates’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$400K Sell
37,111
-40,626
-52% -$549K ﹤0.01% 3184
2021
Q4 		$1.27M Buy
+77,737
New +$1.63M ﹤0.01% 2683

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parametric Portfolio Associates's CTKB Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Cytek Biosciences (CTKB) stake by 52% in Q1 2022, selling an estimated $549K and leaving 37,111 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #3184.

Parametric Portfolio Associates first reported a position in CTKB in Q4 2021 and has held it in 2 quarters since. The position peaked at $1.27M in Q4 2021. 74 funds tracked by Wall St. Rank hold CTKB as of Q1 2022.

  • Parametric Portfolio Associates held 37,111 shares of Cytek Biosciences worth $400K as of Q1 2022.
  • Parametric Portfolio Associates sold 40,626 Cytek Biosciences shares in Q1 2022, an estimated $549K.
  • Cytek Biosciences made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3184 holding.
  • Parametric Portfolio Associates first reported a position in Cytek Biosciences in Q4 2021 and has held it in 2 quarters since.
  • Parametric Portfolio Associates's Cytek Biosciences position peaked at $1.27M in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.